Large scale multifactorial likelihood quantitative analysis of <i>BRCA1</i> and <i>BRCA2</i> variants: An ENIGMA resource to support clinical variant classificationMichael T. Parsons, Capucine Delnatte, Cora M. Aalfs et al.|Human Mutation|2019Cited by 154
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)Benedetta Pellegrino, Antonino Musolino, Luigi Cavanna et al.|ESMO Open|2021Cited by 24
Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)Antonino Musolino, Andrea Ardizzoni, Luigi Cavanna et al.|Cancer Research|2019Cited by 2